COMMUNIQUÉS West-GlobeNewswire

Micron Solutions, Inc. Reports 2018 Third Quarter Results
13/11/2018
FITCHBURG, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Micron Solutions, Inc. (NYSE American: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, [...]
Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System
13/11/2018
Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced it has received [...]
Iovance Biotherapeutics to Participate at November Investor Conferences
13/11/2018
SAN CARLOS, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology [...]
assessURhealth™ named Tampa Bay Tech’s 2018 Emerging Technology Company of the Year
13/11/2018
The disruptive health IT company honored for innovative mental & behavioral health screening technology Tampa, FL, Nov. 13, 2018 (GLOBE NEWSWIRE) -- assessURhealth, LLC , a leading provider of electronic mental and [...]
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
13/11/2018
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ( [...]
CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018
13/11/2018
Sustained anti-cholestatic and anti-inflammatory effects observed with no worsening of pruritus through 52 weeks Results highlight the potential for seladelpar to offer patients an efficacious and safe second line [...]
Forty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business Highlights
13/11/2018
-- Advanced Oncology Pipeline with FSI-189, an Anti-SIRPα Antibody; Investigational New Drug (IND) Application-Enabling Studies Expected to Begin in 2019 – -- New England Journal of Medicine Published Data from Phase 1b [...]
Brainsway Reports Financial Results for Third Quarter of 2018 and Provides Corporate Update
13/11/2018
Third quarter revenues of $4.3 million represent quarterly record and 42% increase over third quarter 2017 Recently commenced installing Deep TMS system for treatment of OCD at U.S. Sites HACKENSACK, N.J., Nov. 13, 2018 [...]
LogicBio to Present at the Jefferies 2018 London Healthcare Conference
13/11/2018
CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet [...]
InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
13/11/2018
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery [...]
BioSig Technologies Announces New Research Program with Mayo Clinic
13/11/2018
New Agreement to Focus on Enhanced Features of PURE EP System and Future Potential Clinical Applications Santa Monica, CA, Nov. 13, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device [...]
Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress
13/11/2018
On Track to Submit First IND for RTX-134 in Q1 2019 CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic [...]
resTORbio Reports Third Quarter 2018 Financial Results
13/11/2018
Additional positive data from Phase 2b trial further support RTB101’s potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly patients Initiation of pivotal Phase 3 program of [...]
Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
13/11/2018
NORCROSS, Ga., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal [...]
scPharmaceuticals Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
13/11/2018
Resubmission of FURSOCIX® with the U.S. Food and Drug Administration (FDA) by year-end 2019 Balance sheet remains strong with over $95 million in cash BURLINGTON, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- [...]
New Study Validates Milestone Scientific’s CompuFlo® Instrument for Epidural Space Identification in Difficult Patients
13/11/2018
Research published in the International Journal of Obstetric Anesthesia finds: Objective identification of the ligamentum flavum and epidural space Difficult blocks rescued in a single attempt Differentiation between [...]
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
13/11/2018
During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . ( [...]
Ortho RTi to Present Further Scientific Validation Data at the Orthopaedic Research Society’s 2019 Annual Meeting
13/11/2018
KIRKLAND, Quebec, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Ortho Regenerative Technologies Inc. ( CSE: ORTH ) (“ Ortho RTi ” or the “ Corporation” ), an emerging Orthopaedic and Sports Medicine technology company, announced [...]
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
13/11/2018
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recessive dystrophic epidermolysis bullosa - EXTON, [...]

Pages